Price$33.10-0.50 (-1.49%)
01:30 PM07:45 PM
News · 26 weeks54+86%
2026-01-252026-07-19
Mix2890d
- Insider15(54%)
- SEC Filings8(29%)
- Other3(11%)
- Analyst2(7%)
Latest news
25 items- INSIDERPresident and COO Bhatt Elizabeth sold $135,974 worth of shares (4,000 units at $33.99) as part of a pre-agreed trading plan and exercised 4,000 shares at a strike of $6.81 (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- INSIDERSVP, Drug Discovery Long Daniel D. exercised 3,333 shares at a strike of $2.76 and sold $114,528 worth of shares (3,333 units at $34.36) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERChief People Officer Shaikhly Samira exercised 2,178 shares at a strike of $6.81 and sold $76,622 worth of shares (2,178 units at $35.18) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Bassan Abraham4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Tong Jeffrey K4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Coulie Bernard4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Sharp Shalini4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Simson Jake4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Gottesdiener Keith Michael4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Director Ezekowitz Alan4 - Septerna, Inc. (0001984086) (Issuer)
- SECSepterna Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- INSIDERSVP, Drug Discovery Long Daniel D. exercised 15,000 shares at a strike of $5.42 and sold $532,582 worth of shares (15,000 units at $35.51) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- INSIDERChief People Officer Shaikhly Samira exercised 6,250 shares at a strike of $11.70 and sold $219,224 worth of shares (6,250 units at $35.08) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- ANALYSTGuggenheim initiated coverage on Septerna with a new price targetGuggenheim initiated coverage of Septerna with a rating of Buy and set a new price target of $52.00
- PRSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual MeetingSepterna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, selective small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism, including robust in vitro and in vivo activity supporting its potential as an oral therapy. SEP-479 is currently being evaluated in an ongoing Phase 1 s
- INSIDERChief People Officer Shaikhly Samira exercised 5,935 shares at a strike of $1.87 and sold $171,682 worth of shares (5,935 units at $28.93) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERChief People Officer Shaikhly Samira exercised 11,798 shares at a strike of $6.81 and sold $354,656 worth of shares (11,798 units at $30.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 10-Q filed by Septerna Inc.10-Q - Septerna, Inc. (0001984086) (Filer)
- SECSepterna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Highlights Business Progress and Reports First Quarter 2026 Financial ResultsCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the first quarter ended Ma
- PRSepterna to Present at Bank of America Securities Health Care ConferenceSOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology compa
SEPN FAQ
6 questionsWhere does SEPN stock trade?
Septerna Inc. (SEPN) is listed on NASDAQ.What sector and industry is SEPN in?
Septerna Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Septerna Inc. go public?
Septerna Inc. (SEPN) completed its IPO in 2024.What are analysts saying about SEPN?
Septerna Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2026-06-11. Recent price targets range from $1400.00 to $4300.00.What companies are similar to SEPN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SEPN side-by-side with any of them on Quantisnow.How can I track SEPN on Quantisnow?
Quantisnow aggregates Septerna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEPN to receive live email and push alerts on every new disclosure.